drugset / Trial / NCT04419259
Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea
Phase 2
Unknown
30 enrolled
Messoud Ashina
Danish Headache Center · collabHerlev and Gentofte Hospital · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
An exploratory open-label study of rosacea patients to study the efficacy and tolerability of erenumab in the prophylactic treatment of persistent redness and flushing attributed to rosacea. Approximately 30 subjects will be included in the study and receive erenumab 140 mg for three months. The study will begin June 2020 and is expected to last nine months.
Timeline
- Start
- 2020-06-09
- Primary completion
- 2021-03
- Completion
- 2021-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erenumab | Monoclonal antibody | 140 mg | Subcutaneous |